We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
WELIREG Merck Sharp & Dohme (Australia) Pty Ltd
Product name
WELIREG
Accepted date
Apr-2026
Active ingredients
belzutifan
Summary of proposed indication
WELIREG (belzutifan), in combination with pembrolizumab, is indicated for the adjuvant treatment of adult patients with renal cell carcinoma (RCC) with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Application type
C (new indication)
Publication date
Apr-2026